MedTrace Logo

Vaccination Response Modulation With a Targeted Rapamycin Protocol Study

NCT07587801 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-14

No results posted yet for this study

Summary

This study will investigate dialysis recipients' responses to important vaccines.

Research suggests that a medication commonly used by transplant recipients may improve vaccine responses. The investigators will be conducting a clinical trial to see whether a short course of low-dose Sirolimus improves the response to vaccination against respiratory syncytial virus (RSV) and influenza (flu) in patient with kidney disease over 60 years old who receive haemodialysis.

Conditions

  • Vaccine Immune Response
  • Haemodialysis Patients
  • Older Adults

Interventions

DRUG

Sirolimus (RAPAMUNE)

All treatment groups will receive 9 doses of 2mg sirolimus over a 3 week period, at varying times relative to vaccination.

BIOLOGICAL

Influenza vaccine (Sequiris Fluad Quad)

All participants will receive a dose of the seasonal Influenza vaccine (Sequiris Fluad Quad)

BIOLOGICAL

RSV vaccine (Pfizer Abrysvo)

All participants will receive a dose of the RSV vaccine (Pfizer Abrysvo)

Sponsors & Collaborators

  • Central Adelaide Local Health Network Incorporated

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07587801 on ClinicalTrials.gov